Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 & Talazoparib for TNBC
Shots:
- The collaboration is for the onset of P-Ib/II trial for assessing Zenith’s ZEN-3694 and Pfizer’s talazoparib in patients with LA or MTNBC
- Pfizer & Zenith to fund the trial with supply of their respective products and will retain rights for their own products
- ZEN-3694 is an inhibitor of BETi (bromodomain and extra-terminal domain inhibitor) currently evaluated in P-II in combination with enzalutamide for metastatic castration resistant prostate cancer
Click here to read full press release/ article | Ref: Zenith Epigenetics | Image: Omniriga